Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: Initial experience

Magnetic Resonance Imaging

Volumn 29, Issue 1, 2011, Pages 83-90

  Lee, Seun Ah ^a   Lee, Chang Hee ^a   Jung, Woon Yong ^a   Lee, Jongmee ^a   Choi, Jae Woong ^a   Kim, Kyeong Ah ^a   Park, Cheol Min ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Gadoxetic acid; Gd EOB DTPA; Green hepatoma; Hepatocellular carcinoma; Liver; MRI

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; BILE SECRETION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOPLASM; DISEASE COURSE; FATTY LIVER; HEPATITIS B; HEPATOBILIARY SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGNAL PROCESSING; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 78649957927     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2010.07.019     Document Type: Article

References (20)

1. Ramalho M., Altun E., Heredia V., Zapparoli M., Semelka R. Liver MR imaging: 1.5T versus 3T. Magn Reson Imaging Clin N Am 2007, 15:321-347.
2. Halavaara J., Breuer J., Ayuso C., et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006, 30:345-354.
3. Hammerstingl R., Huppertz A., Breuer J., et al. Diagnostic efficacy of gadoxetic acid (primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008, 18:457-467.
4. Saito K., Kotake F., Ito N., et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: Quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005, 4:1-9.
5. Ni Y., Marchal G. Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments. Top Magn Reson Imaging 1998, 9:183-195.
6. Ni Y., Marchal G., Yu J., Muhler A., Lukito G., Baert A.L. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994, 4:355-363.
7. Fujita M., Yamamoto R., Takahashi M., et al. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging 1997, 7:768-770.
8. Huppertz A., Haraida S., Kraus A., et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005, 234:468-478.
9. Ishak K.G., Anthony P.P., Solin L.H. Histopathological typing of tumors of the liver 1994, 20. Springer, Berlin, Germany. 2nd ed.
10. Edmondson H.A., Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954, 7:462-503.
11. Pascolo L., Petrovic S., Cupelli F., et al. ABC protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun 2001, 282:60-66.
12. Libra A., Fernetti C., Lorusso V., et al. Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther 2006, 319:809-817.
13. Narita M., Hatano E., Arizono S., et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009, 44:793-798.
14. Hasegawa Y., Nakano S., Ibuka K., et al. Specific diagnosis of hepatocellular carcinoma by delayed hepatobiliary imaging. Cancer 1986, 57:230-236.
15. Okuda K. Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol 1997, 12:S314-318.
16. Murakami T., Baron R., Peterson M., et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996, 200:69-77.
17. Ni Y., Marchal G., Zhang X., et al. The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularixation. Invest Radiol 1993, 28:520-528.
18. Coffin C.M., Diche T., Mahfouz A., et al. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999, 9:444-449.
19. Kim J., Kim M., Park Y., et al. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics. Clin Radiol 2008, 63:1195-1204.
20. Melanie K., Onofrio A., Sanjay S., et al. Hepatobiliary-specific MR contrast agent: role in imaging the liver and biliary tree. Radiographics 2009, 29:1725-1748.